In a significant development, Dow University of Health Sciences (DUHS) has introduced a new anti-rabies vaccine named “Dow Rab,” aimed at combating the rising cases of dog bites in Pakistan. This initiative is a ray of hope for many, especially in Sindh province, where the service is initially being rolled out with plans for nationwide expansion.
The process is straightforward – victims of dog bites can now call and request the vaccine, which will be promptly delivered to their location within 48 hours. This lifesaving vaccine, developed by DUHS, is a testament to local innovation in the medical field.
At the inauguration ceremony led by DUHS Vice-Chancellor Professor Muhammad Saeed Quraishy, it was revealed that 30,000 doses of the vaccine have already been distributed through the network. These doses are manufactured at the Dow Institute of Life Sciences (DILS) using imported raw materials, primarily from China.
However, there’s a bigger vision in sight. Professor Quraishy expressed determination to transition to locally sourced raw materials for vaccine production, thereby reducing dependence on imports. Efforts are underway to ramp up production to meet the demand, with plans to produce an additional 170,000 doses of the anti-rabies vaccine.
The significance of this achievement cannot be overstated. Not only does it address a pressing public health issue, but it also underscores the capabilities of Pakistani institutions in medical research and development.
Furthermore, the affordability factor adds to its importance. A complete course of the vaccine will be available for Rs1,500, making it accessible to a wider population.
This isn’t the first time DUHS has stepped up in the face of a health crisis. During the peak of the COVID-19 pandemic, the university developed IVIG Immunoglobulin, offering a lifeline to numerous patients.
In a strategic move to ensure widespread availability, DUHS has partnered with distribution network Muller & Phipps. Through this collaboration, efforts will be made to make “Dow Rab” accessible across the country gradually.
The urgency for such initiatives is highlighted by statistics revealing that approximately a million people suffer from stray dog bites annually in Pakistan, leading to thousands of deaths due to rabies. The National Institute of Health (NIH) Islamabad has reported an annual requirement of over 2 million doses of anti-rabies vaccine, with a significant portion imported from India.
However, challenges persist, particularly regarding pricing conflicts and shortages. Importers cite currency devaluation as a factor driving up costs, emphasizing the need for local manufacturing to stabilize prices and ensure a steady supply of vaccines.
In essence, the launch of “Dow Rab” marks a significant milestone in Pakistan’s healthcare landscape, offering hope and protection to those vulnerable to rabies, and exemplifying the potential of indigenous solutions to address pressing health challenges.
Leave a Reply